Андреева О. Н., Корочкин И. М., Речнова Н. П., Пивоваров В. Ю. Оценка эффективности, безопасности комбинированного применения периндоприла и индапамида в низких дозах у больных артериальной гипертонией в сочетании с метаболическим синдромом. Кардиоваскулярная терапия и профилактика. 2005;4(3, ч.I):46-52.
1. Ritz E, Hasslacher C, Mann J, Guo Ji-Jhen. Hypertension and vascular disease as complications of diabetes. J Hypertens 1997; 7: 233-40.
2. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37; 1595-607.
3. Kaplan NM. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514-20.
4. Henefeld M, Leonhardt W. Das metabolische Syndrome. Deutsch Ges Wes 1980; 36: 545-51.
5. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease. Part II: Effects of short term-reductions of blood pressure – an overview of the unconfounded randomized drug trials in an epidemiologic context. Lancet 1990: 335: 827-38.
6. Metabolic aspects of Hypertensions. Ed. Norman M. Kaplan. London (UK): Science Press 1994.
7. Taddeei S, Virdis A, Chiadoni L, Salvetti A. The pivotal role of endothelium in hypertension. Medicographia 1999; Issue 59; 21: 22-9.
8. Schiffrin EL, Hayoz D. Angiotensin II Receptor antagonists. Eds. M. Epstein, H.R.Brunner. Philadelphia: Hanley Belfus INC 2001; 279-89.
9. Chalmers J. The importance of drug combinations for effective control of hypertension. Clin Exp Hypertens 1999; 21: 875-84.
10. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI). Arch Intern Med 1997; 157: 2413-46.
11. WHO-ISH Guidelines Sub-Committee. 1999 WHO-ISH Guidelines for the management of mild hypertension. J Hypertens 1999; 17: 151-83.
12. Chalmers J, Castaigne A, Morgan T, Chatang C. Longterm efficacy of a new, fixed, very-low-dose angiotensinconverting enzyme-inhibitor/diuretic combination as firstline therapy in elderly hypertensive patients. J Hypertens 2000; 18: 327-37.
13. Determination of the optimal oral dose of perindopril (2,4 or 8 mg) in combination with indapamide (0.625, 1.25 or 2.5 mg) for 8 weeks in patients with mild-to-moderate essential hypertensions. Randomized double-blind, parallel-group, placeb-controlled stady. Expert report. May 1996.
14. Myers MG, Asmar R, Leenen FHH, Safar M. Fixed low-dose combination therapy in hypertension – a dose response study of perindopril and indapamide. J Hypertsns 2000; 18: 317-25.
15. Castaigne A, Chalmers J, Morgan T, et al. Efficacy and safety of an oral fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination: a randomized, double-blind, placebo-controlled study in elderly patients with mild-to moderate hypertension. Clin Exp Hypertens 1999; 21(7): 1097-110.
16. Machnig T, Engals Henneke KH, et al. Ambulatory blood pressure monitoring: significance of blood pressure variability for progression of heart hypertrophy. Cardiology 1993; 82(3): 187-91.
17. Caro F. Insulin resistance in obese and nonobese man. J Clin Endocrinol Metab 1991; 73: 691-5.
18. National Institutes of Health. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). Bethesda, Md: National Institutes of Health; 2001. NIH Publication 01-3670.
